Solid dispersions with carbamazepine: Optimization of formulation, characterization and examination of long-term stability
Solid dispersions are defined as dispersions of one or more active pharmaceutical ingredients in inert solid-state carriers. They are made with the aim to increase solubility and the dissolution rate of low solubility active pharmaceutical ingredients, with the subsequent increase in their bioavaila...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of Chemical Engineers of Serbia
2018-01-01
|
Series: | Hemijska Industrija |
Subjects: | |
Online Access: | http://www.doiserbia.nb.rs/img/doi/0367-598X/2018/0367-598X1800013K.pdf |
id |
doaj-faefc7cf0ed04707906bbae82c51ac19 |
---|---|
record_format |
Article |
spelling |
doaj-faefc7cf0ed04707906bbae82c51ac192020-11-24T23:29:23ZengAssociation of Chemical Engineers of SerbiaHemijska Industrija 0367-598X2217-74262018-01-0172419120410.2298/HEMIND171025013K0367-598X1800013KSolid dispersions with carbamazepine: Optimization of formulation, characterization and examination of long-term stabilityKrstić Marko0Lukić Igor1Bušatlić Alma2Lazarević Nenad3Vasiljević Dragana4Faculty of Pharmacy, Department of Pharmaceutical Technology and Cosmetology, BelgradeASV Beograd d.o.o., BelgradeAdoc d.o.o., BelgradeInstitute of Physics, Center for Solid State Physics and New Materials, BelgradeFaculty of Pharmacy, Department of Pharmaceutical Technology and Cosmetology, BelgradeSolid dispersions are defined as dispersions of one or more active pharmaceutical ingredients in inert solid-state carriers. They are made with the aim to increase solubility and the dissolution rate of low solubility active pharmaceutical ingredients, with the subsequent increase in their bioavailability. The aim of this study was the development and optimization of solid dispersion formulations with carbamazepine, using D-optimal experimental design, in order to increase the dissolution rate of the selected model drug. By using the method of experimental mixture design, solid dispersions were formulated by varying the ratio of carbamazepine (30-50 %), Gelucire® 44/14 (20-40 %) and Soluplus® polymer (30-50 %) (input parameters). Sixteen formulations were made and used for in vitro testing of the carbamazepine dissolution rate. The observed output parameters were the percentages of carbamazepine released after 10, 20, 30, 45, and 60 minutes. After the data analysis, three test formulations were chosen from different parts of the optimization area. They were prepared and the carbamazepine dissolution rate was determined, followed by stability assessment for 24 months under ambient conditions (25°C, 40 % RH). The highest dissolution rate of carbamazepine from solid dispersions (more than 80 % in 30 minutes) was achieved at the carbamazepine mass fraction of about 40 %, Soluplus® of about 45 % and Gelucire® 44/14 of about 25 %. Comparing the predicted and the experimental obtained release rate profiles of carbamazepine from the three prepared optimized formulations, a significant compliance of the results was observed (f1<15; f2>50). The application of the PAMPA (Parallel Artificial-Membrane Permeability Assay) test has shown that carbamazepine premeability was maintained and mildly increased in two out of the three tested optimzed solid state formulations. Raman spectroscopy, FT-IR and DSC analyes showed that in the three optimized solid dispersions, after preparation and 24 months of storage, interactions between carbamazepine and the excipients were not present and that carbamazepine remained in the single pharmacologically active crystal polymorph form III. Proper selection of solid dispersion proportions of carbamazepine, Gelucire® 44/14 and Soluplus® may significantly increase the dissolution rate of the active substance, and the method of experimental mixture design can be successfully used for optimization of these formulations. [Project of the Serbian Ministry of Education, Science and Technological Development, Grant no. TR34007 and Grant no. ON171032]http://www.doiserbia.nb.rs/img/doi/0367-598X/2018/0367-598X1800013K.pdfsolid dispersionscarbamazepineformulation optimizationexperimental designin vitro releasephysical stability |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Krstić Marko Lukić Igor Bušatlić Alma Lazarević Nenad Vasiljević Dragana |
spellingShingle |
Krstić Marko Lukić Igor Bušatlić Alma Lazarević Nenad Vasiljević Dragana Solid dispersions with carbamazepine: Optimization of formulation, characterization and examination of long-term stability Hemijska Industrija solid dispersions carbamazepine formulation optimization experimental design in vitro release physical stability |
author_facet |
Krstić Marko Lukić Igor Bušatlić Alma Lazarević Nenad Vasiljević Dragana |
author_sort |
Krstić Marko |
title |
Solid dispersions with carbamazepine: Optimization of formulation, characterization and examination of long-term stability |
title_short |
Solid dispersions with carbamazepine: Optimization of formulation, characterization and examination of long-term stability |
title_full |
Solid dispersions with carbamazepine: Optimization of formulation, characterization and examination of long-term stability |
title_fullStr |
Solid dispersions with carbamazepine: Optimization of formulation, characterization and examination of long-term stability |
title_full_unstemmed |
Solid dispersions with carbamazepine: Optimization of formulation, characterization and examination of long-term stability |
title_sort |
solid dispersions with carbamazepine: optimization of formulation, characterization and examination of long-term stability |
publisher |
Association of Chemical Engineers of Serbia |
series |
Hemijska Industrija |
issn |
0367-598X 2217-7426 |
publishDate |
2018-01-01 |
description |
Solid dispersions are defined as dispersions of one or more active pharmaceutical ingredients in inert solid-state carriers. They are made with the aim to increase solubility and the dissolution rate of low solubility active pharmaceutical ingredients, with the subsequent increase in their bioavailability. The aim of this study was the development and optimization of solid dispersion formulations with carbamazepine, using D-optimal experimental design, in order to increase the dissolution rate of the selected model drug. By using the method of experimental mixture design, solid dispersions were formulated by varying the ratio of carbamazepine (30-50 %), Gelucire® 44/14 (20-40 %) and Soluplus® polymer (30-50 %) (input parameters). Sixteen formulations were made and used for in vitro testing of the carbamazepine dissolution rate. The observed output parameters were the percentages of carbamazepine released after 10, 20, 30, 45, and 60 minutes. After the data analysis, three test formulations were chosen from different parts of the optimization area. They were prepared and the carbamazepine dissolution rate was determined, followed by stability assessment for 24 months under ambient conditions (25°C, 40 % RH). The highest dissolution rate of carbamazepine from solid dispersions (more than 80 % in 30 minutes) was achieved at the carbamazepine mass fraction of about 40 %, Soluplus® of about 45 % and Gelucire® 44/14 of about 25 %. Comparing the predicted and the experimental obtained release rate profiles of carbamazepine from the three prepared optimized formulations, a significant compliance of the results was observed (f1<15; f2>50). The application of the PAMPA (Parallel Artificial-Membrane Permeability Assay) test has shown that carbamazepine premeability was maintained and mildly increased in two out of the three tested optimzed solid state formulations. Raman spectroscopy, FT-IR and DSC analyes showed that in the three optimized solid dispersions, after preparation and 24 months of storage, interactions between carbamazepine and the excipients were not present and that carbamazepine remained in the single pharmacologically active crystal polymorph form III. Proper selection of solid dispersion proportions of carbamazepine, Gelucire® 44/14 and Soluplus® may significantly increase the dissolution rate of the active substance, and the method of experimental mixture design can be successfully used for optimization of these formulations. [Project of the Serbian Ministry of
Education, Science and Technological Development, Grant no. TR34007 and Grant
no. ON171032] |
topic |
solid dispersions carbamazepine formulation optimization experimental design in vitro release physical stability |
url |
http://www.doiserbia.nb.rs/img/doi/0367-598X/2018/0367-598X1800013K.pdf |
work_keys_str_mv |
AT krsticmarko soliddispersionswithcarbamazepineoptimizationofformulationcharacterizationandexaminationoflongtermstability AT lukicigor soliddispersionswithcarbamazepineoptimizationofformulationcharacterizationandexaminationoflongtermstability AT busatlicalma soliddispersionswithcarbamazepineoptimizationofformulationcharacterizationandexaminationoflongtermstability AT lazarevicnenad soliddispersionswithcarbamazepineoptimizationofformulationcharacterizationandexaminationoflongtermstability AT vasiljevicdragana soliddispersionswithcarbamazepineoptimizationofformulationcharacterizationandexaminationoflongtermstability |
_version_ |
1725545991363362816 |